A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
← catalyst calendarSponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
762actual
Sites
331
Countries
Argentina, Australia, Austria +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-21 | actual | When the study began enrolling |
| Primary completion | 2026-05-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-17 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: sigvotatug vedotin — also filed as SGN-B6A; PF-08046047
- Drug: docetaxel
Primary outcome
what the primary-completion date above is the date OFOverall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)
measured Approximately 5 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed